Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

Freyer, Craig W.; Carulli, Alison; Gier, Shannon; Ganetsky, Alex; Timlin, Colleen; Schuster, Mindy G.; Babushok, Daria V.; Frey, Noelle V.; Gill, Saar; Hexner, Elizabeth O.; Luger, Selina M.; Mangan, James K.; Martin, Mary Ellen; McCurdy, Shannon R.; Perl, Alexander E.; Porter, David; Pratz, Keith W.; Smith, Jacqueline; Stadtmauer, Edward A.; Loren, Alison W.

doi:10.1080/10428194.2022.2042686

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four retrospective studies 22 , 38 , 46 , 47 including 206 patients reported the CMV activation at 200 days after HSCT. The incidence of CMV activation at 200 days after allo-HSCT was 49% (95% CI, 32%–67%, Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Letermovir is a 3,4-dihydro-quinazoline-4-yl-acetic acid derivative that inhibits viral terminase complex inhibitor 18 , 19 Several studies observe that letermovir can prevent CMV activation after allo-HSCT. 20 – 22 However, most of them were retrospective studies and the efficacy of CMV prophylaxis was inconsistent among these studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation

Li,

Zhang,

Shen

et al. 2024

Blood Science

View full text Add to dashboard Cite

Letermovir is a specific inhibitor of cytomegalovirus (CMV) terminase complex. Several studies have reported that letermovir can effectively prevent CMV activation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of letermovir prophylaxis for CMV infection after allo-HSCT with a systemic review and meta-analysis. A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. PubMed and Embase databases were searched. A total of 28 studies were included. The incidence of CMV activation at 14 weeks after HSCT was 0.10 (95% confidence interval [CI], 0.06–0.18), which was 0.10 (95% CI, 0.04–0.21) and 0% in adult and children (2 studies were included and both of them were 0%). In addition, the incidence of CMV activation at 14 weeks after allo-HSCT was 0.11 (95% CI, 0.06–0.21) and 0.07 (only 1 study included), respectively, in retrospective and prospective studies. The incidence of CMV activation at 100 and 200 days after HSCT was 0.23 (95% CI, 0.16–0.33) and 0.49 (95% CI, 0.32–0.67), respectively. The incidence of CMV disease at 14 weeks and at 6 months after HSCT was 0.01 (95% CI, 0.01–0.02) and 0.03 (95% CI, 0.01–0.09), respectively. Thus, our systemic review and meta-analysis suggested that letermovir prophylaxis was safe and effective for CMV activation after allo-HSCT.

show abstract